Nov. 26th, 10am local time in NYC, NASDAQ has featured Eukarÿs on its giant screen in Times Square, for having both:

1 – won the 2025 Grand Prize of Biotools Innovator, the only startup accelerator dedicated to Life Sciences Tools, after an extremely selective process, which had started early 2025 with 440 candidates from 43 countries,

2 – been selected by BARDA as member of the Vanguard acceleration program, focused on enabling technologies identified as critical for responsiveness in case of health crisis like pandemics or bioterrorist attacks.

After an extremely selective process throughout the year 2025 Eukarÿs reaches a historic “double hit” in acceleration programs in the US

1. Eukarÿs is the Winner of the 2025 BioTools Innovator Grand Prize, receiving a $250,000 award. Eukarÿs was in competition with 440 companies from 43 countries. The final took place at the Capstone event in San Diego, where Eukarÿs was the only non-US company. The selection has been made by vote by 80+ industry-leaders of the Life-Sciences Tools industry.

And

2. Eukarÿs has been selected by the U.S. government agency BARDA as one of the ten startups admitted into VANGUARD, its accelerator dedicated to enabling technologies for national health preparedness.

These distinctions, both awarded in the United States, the world’s largest and most competitive biotech and bioproduction ecosystem, represent a remarkable recognition of Eukarÿs deeptech innovation on the global stage.